P2493Change in cardiovascular health and incident type 2 diabetes and prediabetes: The Whitehall II Study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
R Climie ◽  
T T Van Sloten ◽  
M C Perier ◽  
M Tafflet ◽  
A Fayosse ◽  
...  

Abstract Background Most previous studies on cardiovascular health (CVH) and incident type 2 diabetes (T2D) used a single measure of CVH and none investigated the association with incident prediabetes. This study aimed to examine whether changes in CVH are associated with incident T2D and prediabetes. Methods Within the prospective Whitehall II study, CVH was examined serially every 5 years from 1991/93 until 2015/16. Subjects with 0–2, 3–4 and 5–6 ideal metrics of CVH from the American Heart Association (non-smoking, and ideal levels of body mass index, physical activity, diet, blood pressure, and total cholesterol, fasting glycaemia was not considered),were categorized as having low, moderate or high CVH. Results There were 6234 participants without prior cardiovascular disease and T2D (mean age 49.8±6.0 years, 70% male) including 5015 who were additionally free of prediabetes (49.6±6.0 years, 67% male) at baseline. Over a median follow-up of 24.8 (IQR 24.0 to 25.2) years, 895 and 1703 incident cases of T2D and prediabetes occurred respectively. Change in CVH between 1991/93 and 2002/04 was calculated among 4470 participants without CVD and T2D in the interval, and among 2798 participants additionally free of prediabetes. In multivariate analysis, compared to those with stable low CVH, risk of T2D was lower in those with initially high CVH (HR=0.23; 0.09, 0.56), those who had persistently moderate CVH or changed from moderate to high CVH (moderate-moderate/high; HR=0.42; 0.33, 0.54), low-moderate/high (HR=0.50; 0.36, 0.69) and moderate-low (HR=0.63; 0.48, 0.83). Results were similar for prediabetes, but effect sizes were smaller. Conclusions Among participants without previous CVD, T2D or prediabetes, change in CVH was related to the risk of incident T2D and prediabetes.

2021 ◽  
Author(s):  
Guo-Chong Chen ◽  
Rhonda Arthur ◽  
Li-Qiang Qin ◽  
Li-Hua Chen ◽  
Zhendong Mei ◽  
...  

<b>OBJECTIVE </b> <p>To evaluate associations of oily and non-oily fish consumption and fish oil supplements with incident type 2 diabetes (T2D).</p> <p><b>RESEARCH DESIGN AND METHODS </b></p> <p>We included<a> 392,287 middle-aged and older participants </a>(55.0% women) in the UK Biobank who were free of diabetes, major cardiovascular disease, and cancer, and had information on habitual intake of major food groups and use of fish oil supplements at baseline (<a>2006-2010</a>). Of these, <a>163,706</a> participated in 1-5 rounds of 24-h dietary recalls during 2009-2012. </p> <p><b>RESULTS</b></p> <p>During a median 10.1 years of follow-up, <a>7,262</a> incident cases of T2D were identified. As compared with participants who reported never consumption of oily fish, the multivariable-adjusted hazard ratios (95% CI) of T2D were 0.84 (0.78-0.91), 0.78 (0.72-0.85), and 0.78 (0.71-0.86) for those who reported <1 serving/week, weekly, and ≥2 servings/week of oily fish consumption, respectively (P-trend <0.001). Consumption of non-oily fish was not associated with risk of T2D (P-trend = 0.45). Participants who reported regular fish oil use at baseline had a 9% (95% CI: 4%-14%) lower risk of T2D as compared with non-users. Baseline regular users of fish oil who also reported fish oil use during at least one of the 24-h dietary recalls had an 18% (95% CI: 8%-27%) lower risk of T2D when compared with constant non-users.</p> <p><b>CONCLUSIONS</b></p> Our findings suggest that consumption of oily fish, but not non-oily fish, was associated with a lower risk of T2D. Use of fish oil supplements, especially constant use over time, was also associated with a lower risk of T2D.


Diabetes Care ◽  
2019 ◽  
Vol 42 (10) ◽  
pp. 1981-1987 ◽  
Author(s):  
Rachel E. Climie ◽  
Thomas T. van Sloten ◽  
Marie-Cécile Périer ◽  
Muriel Tafflet ◽  
Aurore Fayosse ◽  
...  

Diabetologia ◽  
2016 ◽  
Vol 59 (9) ◽  
pp. 1893-1903 ◽  
Author(s):  
Joshua J. Joseph ◽  
Justin B. Echouffo-Tcheugui ◽  
Mercedes R. Carnethon ◽  
Alain G. Bertoni ◽  
Christina M. Shay ◽  
...  

2013 ◽  
Vol 98 (8) ◽  
pp. E1352-E1359 ◽  
Author(s):  
Ali Abbasi ◽  
Eva Corpeleijn ◽  
Ron T. Gansevoort ◽  
Rijk O. B. Gans ◽  
Hans L. Hillege ◽  
...  

Background and Aims: High-density lipoproteins (HDLs) may directly stimulate β-cell function and glucose metabolism. We determined the relationships of fasting high-density lipoprotein cholesterol (HDL-C), plasma apolipoprotein (apo) A-I and apoA-II, and HDL-C–to–apoA-I and HDL-C–to–apoA-II ratios, as estimates of HDL particle composition, with incident type 2 diabetes mellitus. Methods: A prospective study was carried out in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort after exclusion of subjects with diabetes at baseline (n = 6820; age, 28–75 years). The association of HDL-related variables with incident type 2 diabetes was determined by multivariate logistic regression analyses. Results: After a median follow-up of 7.7 years, 394 incident cases of type 2 diabetes mellitus were ascertained (5.8%). After adjustment for age, sex, family history of diabetes, body mass index, hypertension, alcohol, and smoking, odd ratios (ORs) for diabetes were 0.55 (95% confidence interval [CI], 0.47–0.64; P &lt; .001), 0.81 (0.71–0.93; P = .002), 0.02 (0.01–0.06; P &lt; .001), and 0.03 (0.01–0.060; P &lt; .001) per 1-SD increase in HDL-C and apoA-I and in the HDL-C–to–apoA-I and the HDL-C–to–apoA-II ratios, respectively. In contrast, apoA-II was not related to incident diabetes (OR = 1.02; 95% CI, 0.90–1.16; P=0.71). The relationships of HDL-C and the ratios of HDL-C to apoA-I and HDL-C to apoA-II remained significant after further adjustment for baseline glucose and triglycerides (ORHDL = 0.74 [95% CI, 0.61–0.88], ORHDL/APO A-I = 0.14 [0.04–0.44], and ORHDL/APOA-II = 0.12 [0.04–0.36]; all P ≤ .001). Conclusions: Higher HDL-C, as well as higher HDL-C–to–apoA-I and HDL-C–to–apoA-II ratios are strongly and independently related to a lower risk of future type 2 diabetes.


2021 ◽  
Author(s):  
Guo-Chong Chen ◽  
Rhonda Arthur ◽  
Li-Qiang Qin ◽  
Li-Hua Chen ◽  
Zhendong Mei ◽  
...  

<b>OBJECTIVE </b> <p>To evaluate associations of oily and non-oily fish consumption and fish oil supplements with incident type 2 diabetes (T2D).</p> <p><b>RESEARCH DESIGN AND METHODS </b></p> <p>We included<a> 392,287 middle-aged and older participants </a>(55.0% women) in the UK Biobank who were free of diabetes, major cardiovascular disease, and cancer, and had information on habitual intake of major food groups and use of fish oil supplements at baseline (<a>2006-2010</a>). Of these, <a>163,706</a> participated in 1-5 rounds of 24-h dietary recalls during 2009-2012. </p> <p><b>RESULTS</b></p> <p>During a median 10.1 years of follow-up, <a>7,262</a> incident cases of T2D were identified. As compared with participants who reported never consumption of oily fish, the multivariable-adjusted hazard ratios (95% CI) of T2D were 0.84 (0.78-0.91), 0.78 (0.72-0.85), and 0.78 (0.71-0.86) for those who reported <1 serving/week, weekly, and ≥2 servings/week of oily fish consumption, respectively (P-trend <0.001). Consumption of non-oily fish was not associated with risk of T2D (P-trend = 0.45). Participants who reported regular fish oil use at baseline had a 9% (95% CI: 4%-14%) lower risk of T2D as compared with non-users. Baseline regular users of fish oil who also reported fish oil use during at least one of the 24-h dietary recalls had an 18% (95% CI: 8%-27%) lower risk of T2D when compared with constant non-users.</p> <p><b>CONCLUSIONS</b></p> Our findings suggest that consumption of oily fish, but not non-oily fish, was associated with a lower risk of T2D. Use of fish oil supplements, especially constant use over time, was also associated with a lower risk of T2D.


2020 ◽  
Author(s):  
Anna Birukov ◽  
Fabian Eichelmann ◽  
Olga Kuxhaus ◽  
Elli Polemiti ◽  
Andreas Fritsche ◽  
...  

<b>Objective:</b> Circulating N-terminal pro b-type natriuretic peptide (NT-proBNP) is a classic diagnostic and prognostic marker for heart failure. However, it is inversely associated with diabetes risk. We aimed to investigate relationships of NT-proBNP with risk of diabetes-related complications in initially healthy individuals. <p><b>Research Design and Methods:</b> <a>We performed a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort including a random subcohort (n=1294) and incident cases of type 2 diabetes (n=649) and cardiovascular diseases (CVD, n=478). Incident cases of type 2 diabetes (n=545) were followed up for micro- (n=133) and macrovascular (n=50) complications. Plasma NT-proBNP was measured at baseline in initially healthy participants.</a></p> <p><b>Results: </b><a></a><a>In multivariable models, NT-proBNP was linearly inversely associated with incident type 2 diabetes, HR (95% CI) per doubling in NT-proBNP: 0.91 (0.86; 0.98). The association was only observable in women, HR (95%CI): 0.80 (0.72; 0.90), compared to 0.98 (0.91; 1.07) in men. Among persons with incident diabetes, NT-proBNP was positively associated with diabetes complications, HR (95% CI): 1.31 (1.13; 1.53) for overall, 1.20 (1.01; 1.43) for micro- and 1.37 (1.03; 1.83) for macrovascular complications. </a></p> <b>Conclusions: </b><a>Although higher NT-proBNP levels are associated with lower diabetes risk, in persons who develop diabetes NT-proBNP is a biomarker for vascular complications independent of potential confounders. </a><a>Thus, NT-proBNP might be informative to monitor risk for diabetes-related micro- and macrovascular complications, which should be further explored in future prospective studies.</a>


Diabetes Care ◽  
2015 ◽  
Vol 38 (6) ◽  
pp. 1099-1107 ◽  
Author(s):  
Qianyi Wang ◽  
Fumiaki Imamura ◽  
Wenjie Ma ◽  
Molin Wang ◽  
Rozenn N. Lemaitre ◽  
...  

2020 ◽  
Author(s):  
Anna Birukov ◽  
Fabian Eichelmann ◽  
Olga Kuxhaus ◽  
Elli Polemiti ◽  
Andreas Fritsche ◽  
...  

<b>Objective:</b> Circulating N-terminal pro b-type natriuretic peptide (NT-proBNP) is a classic diagnostic and prognostic marker for heart failure. However, it is inversely associated with diabetes risk. We aimed to investigate relationships of NT-proBNP with risk of diabetes-related complications in initially healthy individuals. <p><b>Research Design and Methods:</b> <a>We performed a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort including a random subcohort (n=1294) and incident cases of type 2 diabetes (n=649) and cardiovascular diseases (CVD, n=478). Incident cases of type 2 diabetes (n=545) were followed up for micro- (n=133) and macrovascular (n=50) complications. Plasma NT-proBNP was measured at baseline in initially healthy participants.</a></p> <p><b>Results: </b><a></a><a>In multivariable models, NT-proBNP was linearly inversely associated with incident type 2 diabetes, HR (95% CI) per doubling in NT-proBNP: 0.91 (0.86; 0.98). The association was only observable in women, HR (95%CI): 0.80 (0.72; 0.90), compared to 0.98 (0.91; 1.07) in men. Among persons with incident diabetes, NT-proBNP was positively associated with diabetes complications, HR (95% CI): 1.31 (1.13; 1.53) for overall, 1.20 (1.01; 1.43) for micro- and 1.37 (1.03; 1.83) for macrovascular complications. </a></p> <b>Conclusions: </b><a>Although higher NT-proBNP levels are associated with lower diabetes risk, in persons who develop diabetes NT-proBNP is a biomarker for vascular complications independent of potential confounders. </a><a>Thus, NT-proBNP might be informative to monitor risk for diabetes-related micro- and macrovascular complications, which should be further explored in future prospective studies.</a>


Sign in / Sign up

Export Citation Format

Share Document